Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XINACT neoadjuvant capecitabine plus AC-docetaxel study in large or locally advanced breast cancer
2007-003221-25Phase 2Completed
- Sponsor
- United Lincolnshire Teaching Hospitals NHS Trust
- Start
- Jul 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, doxorubicin, cyclophosphamide and docetaxel in breast cancer, sponsored by United Lincolnshire Teaching Hospitals NHS Trust. Primary endpoint: Pathologic complete response. Started Jul 2007; status: completed.
02
Drugs
capecitabinedoxorubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-003221-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003221-25.